Today: 9 April 2026
Subscribe
Browse Category

NYSE:NVO 14 January 2026 - 4 February 2026

Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Novo Nordisk shares fell 16% in Copenhagen after the company warned 2026 sales and profit may drop up to 13% due to falling U.S. drug prices and tougher competition. ADRs slid nearly 4% in New York. Novo plans a share buyback of up to 15 billion Danish crowns and named Jamey Millar as its new U.S. head. CEO Mike Doustdar said Wegovy price cuts have hit results but are meant to boost future demand.
4 February 2026
···
Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk warned adjusted sales and operating profit may fall 5% to 13% in 2026, citing U.S. price cuts and rising competition from Eli Lilly. Shares plunged 18% in early Copenhagen trading. CEO Mike Doustdar called the U.S. price reductions for Wegovy “painful.” Novo also flagged patent expiries and pressure from compounded GLP-1 drugs.
4 February 2026
···
Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly shares fell 3.9% to $1,003.46 on Tuesday, tracking a sharp 14% drop in Novo Nordisk after its 2026 forecast signaled deeper pricing pressure in the obesity-drug market. Pfizer also slipped on new weight-loss drug data. Lilly will report quarterly results Wednesday, as investors watch for signs of further price cuts and shifting demand in the sector.
4 February 2026
····
Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly shares fell 1.4% to $1,029.99 by midday Tuesday as U.S. prices for GLP-1 obesity drugs dropped sharply, prompting analysts to cut long-term forecasts. Novo Nordisk and Pfizer reported strong weight-loss data for rival drugs this week, intensifying competition. Investors await Lilly’s earnings update Wednesday for signals on pricing, demand, and supply outlooks.
3 February 2026
·····
Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings

Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings

Eli Lilly shares rose 1.5% to close near $1,052.70 Monday, recovering from early losses ahead of its earnings report due Wednesday. Analysts have cut long-term forecasts for obesity drugs as prices fall and competition intensifies, with 2030 sales estimates for GLP-1 drugs dropping to about $100 billion. Investors are focused on Lilly’s pricing strategy and demand outlook. The FDA is set to rule on Lilly’s weight-loss pill by April 10.
2 February 2026
····
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
······
Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

The Health Care Select Sector SPDR Fund (XLV) fell 0.5% to $157.48 Friday, with Eli Lilly down 2.1%. Johnson & Johnson and UnitedHealth posted small gains. Traders are watching obesity-drug demand and a crowded earnings calendar next week. The FDA linked ByHeart’s recalled infant formula to a multi-state botulism outbreak.
25 January 2026
·····
Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week

Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week

Eli Lilly shares fell 2.1% to $1,064.29 Friday after analysts reported Novo Nordisk’s new Wegovy pill logged 18,410 U.S. prescriptions in its first full week. Lilly’s Q4 results are due Feb. 4. India approved local firms to make generic semaglutide ahead of its 2026 patent expiry. New data showed many patients did not quickly regain weight after stopping GLP-1 drugs.
24 January 2026
···
Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly shares fell 1.1% to $1,075.78 after Novo Nordisk’s new Wegovy pill logged over 18,000 U.S. prescriptions in its first full week. Investors are watching ahead of Lilly’s Feb. 4 earnings and an expected FDA decision on its own oral obesity drug by April. Several Lilly directors recently received stock units through a deferral plan.
23 January 2026
····
Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

Novo Nordisk shares rose 4.9% to $62.23 in premarket trading after new data showed U.S. prescriptions for the oral Wegovy pill jumped to 20,392 from 4,286. The surge comes as investors watch prescription trends ahead of Novo’s Feb. 4 results. Rival Eli Lilly shares edged up 0.8%. India’s Sun Pharmaceutical won approval to produce generic semaglutide after the patent expires in March.
23 January 2026
·
Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Novo Nordisk shares surged 6.49% to 388.90 Danish crowns Friday after early U.S. prescription data for its new Wegovy pill and UK approval of a higher Wegovy dose. U.S. retail pharmacies filled 3,071 Wegovy pill prescriptions in the first four days, not counting online sales. Novo’s ADRs rose 0.74% in New York. Investors await the company’s earnings report on Feb. 4.
18 January 2026
·
Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk shares surged 6.5% in Copenhagen and 9.1% in New York after early U.S. prescription data showed 3,071 Wegovy pill scripts filled in four days. Britain approved a higher maximum dose of Wegovy for obesity patients. A Texas compounding pharmacy sued Novo and Eli Lilly over alleged market dominance. Novo called the lawsuit “without merit.”
17 January 2026
···
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer shares fell 0.6% to $25.42 in late-morning trading Thursday as U.S. vaccine policy changes fueled uncertainty. Sanofi warned of weaker U.S. vaccine demand; Pfizer’s CEO criticized the new recommendations. Moderna and Merck also traded lower. Investors await Pfizer’s Feb. 3 results for updates on 2026 outlook and new product pipeline.
15 January 2026
········
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics (GPCR) shares surged 7.5% to $83.76 Wednesday on over 1 million shares traded, fueled by buyout speculation and renewed interest in oral obesity drugs. Novo Nordisk executives signaled openness to acquisitions, while Structure reported Phase 2b data showing its oral GLP-1 drug aleniglipron led to 11.3% placebo-adjusted weight loss at 36 weeks. Viking Therapeutics and Terns Pharmaceuticals also rose sharply.
14 January 2026
······
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer shares rose 1.4% to $25.51 Wednesday morning, outpacing a broader market decline. CEO Albert Bourla said the company misjudged the cash-pay obesity drug market and plans about 10 Phase 3 obesity trials in 2026. Investors are watching for Feb. 3 results and updates on late-stage trial launches. Pfizer expects no revenue growth before 2029 as it faces major patent expirations.
14 January 2026
·····
1 2 3 4 … 7

Stock Market Today

  • Notable Options Trading Activity in INTU, LRCX, SANM on Thursday
    April 9, 2026, 5:11 PM EDT. Thursday saw significant options trading volume in Intuit Inc (INTU), Lam Research Corp (LRCX), and Sanmina Corp (SANM), key components of the Russell 3000 index. INTU's options totalled 15,526 contracts, nearly 54.4% of its average daily share volume, with high activity on the $370 call expiring April 2026. LRCX options reached 53,078 contracts, some 51.9% of average daily volume, led by the $237.50 put expiring the same date. SANM saw 3,419 contracts traded, about 51.6% of its average, highlighting the $150 call for April 2026. This notable activity reflects heightened trader interest ahead of next year's April expirations.

Latest article

Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

9 April 2026
Tesla is developing a lower-cost compact SUV, with initial production planned for Shanghai, Reuters reported Thursday. The company built 408,386 vehicles and delivered 358,023 in the first quarter, leaving its widest gap in at least four years. Reuters said the new SUV likely will not reach production this year. Tesla did not respond to questions about the project.
NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

9 April 2026
NIO opened pre-orders for its ES9 flagship SUV Thursday, pricing it at 528,000 yuan with battery or 420,000 yuan under its Battery-as-a-Service plan. March deliveries rose 136% year-on-year, but NIO’s U.S. shares fell 4.9% after the announcement. The ES9 enters a shrinking premium SUV market in China, competing with Li Auto and Aito. CEO William Li warned chip shortages could add up to 10,000 yuan per vehicle.
Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

9 April 2026
Plug Power shares rose 2.5% to $2.715 Thursday after the company reaffirmed its target of positive EBITDAS by end-2026 and projected up to $200 million in savings from Project Quantum Leap. The update followed a major electrolyzer project win in Quebec and investor meetings in Toronto and Montreal. Plug reported 2025 revenue of $710 million and a fourth-quarter gross profit of $5.5 million.
Oil Prices Today: Brent, WTI Rebound as Fragile Iran Ceasefire Leaves Hormuz Choked

Oil Prices Today: Brent, WTI Rebound as Fragile Iran Ceasefire Leaves Hormuz Choked

9 April 2026
Oil prices rebounded Thursday as traffic through the Strait of Hormuz stayed below 10% of normal, with just seven ships passing in 24 hours. Brent crude rose 1% to $95.65 a barrel, while U.S. WTI climbed 3.2% to $97.39. North Sea Forties crude hit a record $146.43. Major shippers and banks warned supply disruptions could persist for weeks despite the U.S.-Iran ceasefire.
Natural Gas Price Today: Europe’s TTF Holds Near €44 as EU Says Supply Is Safe for Now

Natural Gas Price Today: Europe’s TTF Holds Near €44 as EU Says Supply Is Safe for Now

9 April 2026
European natural gas prices hovered near 44 euros per megawatt hour Thursday after a 15% drop in the Dutch TTF benchmark. Brussels reported no immediate supply risk from the Iran crisis, but ship traffic through the Strait of Hormuz remained below 10% of normal. QatarEnergy restarted some LNG production, though full recovery depends on shipping. Goldman Sachs cut its TTF price forecast, citing possible volatility if disruptions persist.
Go toTop